Head of global pharma group suggests pandemic ‘social contract’
The president of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) says rich industrialised countries and the pharmaceutical industry must prepare for the next pandemic. Critical of vaccine nationalism, Thomas Cueni wants to ensure that poorer countries get access to vaccines faster when crises hit.
This content was published on
2 minutes
www.swissinfo.ch/ds
العربية
ar
رئيس مجموعة شركات الأدوية العالمية يقترح «عقدا اجتماعيا» لمكافحة الأوبئة
What is needed is a kind of social contract, argues Cueni in an interview published by the SonntagsZeitung newspaper. He says industry is prepared to reserve part of the production for poorer countries. In return, rich countries must provide initiatives like COVAX (COVID-19 Vaccine Global Access Facility) with enough funding to buy the reserved production.
Vaccination priority should be given to people who work in healthcare or are over 65 years old, he says, respectively 1% and 8% of the global population.
“A willingness on the part of companies to reserve part of the production for these population groups in poorer countries right from the start in the event of a pandemic could be a real game changer,” he says.
Vaccine nationalism
Cueni notes that rich countries engaged in a kind of hedging at the beginning of the Covid-19 pandemic. They ordered all promising vaccines to ensure they have the vaccine that ultimately gets approved. Then they hoarded vaccines on a large scale. “This vaccine nationalism was the big problem,” he says.
Africa, in particular, was left behind. “Therefore, by 2040, Africa wants to cover around 60% of its vaccination needs from its own production,” he notes. “But that doesn’t happen overnight, because an entire infrastructure has to be set up.”
The costs of a pandemic preparedness fund pale in comparison with the costs of the pandemic, he notes, citing calculations by the International Monetary Fund (IMF). Such a fund would require around $20 billion. The Covid-19 pandemic is expected to cost $13.8 trillion by 2024.
Based in Geneva, IFPMA represents the biopharmaceutical industry at the global level. Cueni has been at the helm of the organisation since 2017, having previously served as secretary general of Interpharma, the association of pharmaceutical research companies in Switzerland.
Popular Stories
More
Swiss Abroad
Feline felons: what to do with Switzerland’s killer cats?
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Swiss National Park criticises wolf pack cull plans
This content was published on
The Swiss National Park slams plans by canton Graubünden's to eliminate an entire wolf pack resident in the protected wilderness zone.
Swiss city returns painting to Poland after provenance probe
This content was published on
The "Self-Portrait at the Age of 72" by Anton Graff, which disappeared during WWII, is returned by Winterthur to Poland..
Replica Hiroshima tricycle exhibits at Red Cross Museum
This content was published on
A bronze replica of a tricycle found in 1945 after the atomic explosion in Hiroshima has been on display at the International Red Cross Museum in Geneva.
Zurich Film Festival to host 35 world or European premieres
This content was published on
A host of stars are expected at this year's Zurich Film Festival (ZFF), which celebrates its 20th anniversary on October 3.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19: Switzerland can smile again. But for how long?
This content was published on
While Switzerland is back to normal, countries like China struggle to contain the pandemic. Elsewhere, people haven't received their first jab yet.
This content was published on
Public health experts are cautious about lifting Covid-19 restrictions. One key reason is that we still can't test for our immunity to the virus.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.